With CAR T-cell therapies becoming mainstream in oncology and autoimmune diseases, Sino Biological offers an integrated platform of validated bioreagents supporting all phases of CAR T-cell development. This includes discovery antibodies, serum-free media for viral packaging, GMP-grade cytokines for expansion, and quality control reagents. These comprehensive services aim to enhance reproducibility and facilitate scaling to clinical manufacturing settings, addressing workflow bottlenecks in immunotherapy innovation.